Clinical trials · Illinois
Cancer clinical trials in Illinois
We’re tracking 679 recruiting cancer studies with a site in Illinois — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT03729115Recruiting
Enhanced breast cancer screening for high-risk women
This study tests a more thorough breast cancer screening program using MRI and other imaging for women at high risk. It aims to detect cancer earlier, which may improve treatment options and outcomes.
Chicago, IllinoisAges 25 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Zion, IllinoisAges 18 years+ - NCT03193970Recruiting
Study recovery after bladder removal surgery
This trial looks at how patients recover after radical cystectomy, a surgery that removes the bladder for bladder cancer. It will study recovery patterns to help understand what recovery may look like and possibly improve care.
Chicago, IllinoisAges 18 years+ - NCT02474160Recruiting
Banking cancer tissue and blood for future research
This study collects and stores leftover or newly taken samples of tissue and blood from people with cancer. The goal is to build a research library that can help investigators study cancer and develop better tests or treatments.
Bloomington, IllinoisAges 2 months+ - NCT02620852Recruiting
Wisdom Study: Women’s breast cancer screening decisions
This study looks at how to decide the best breast cancer screening (like mammograms) based on your personal risk. It may help by testing a smarter way to match screening to your risk level.
Chicago, IllinoisAges 30–74 - NCT01492972RecruitingPhase 3
Lighter radiation, with or without hormone suppression
This Phase 3 trial tests whether giving a smaller amount of radiation (“hypo-fractionated” means fewer, larger sessions) can work as well as standard approaches for intermediate-risk prostate cancer. It also compares adding hormone therapy (“androgen suppression”) to radiation versus using radiation alone.
Warrenville, IllinoisAges 18 years+ - NCT00969111Recruiting
Radiation after prostate surgery for prostate cancer without nodal spread
This trial looks at radiation therapy given after prostate surgery (or if needed later) for prostate cancer where lymph nodes were not involved. It may help patients whose PSA rises or who need additional treatment to reduce the chance the cancer comes back.
Warrenville, IllinoisAges 18 years+ - NCT01120353Recruiting
Childhood cancer survivors study to understand long-term health
This study follows people who survived certain childhood cancers to learn what long-term health effects may happen after treatment. It also compares survivors with siblings to help researchers understand differences that may be related to cancer or treatment.
Chicago, IllinoisAges Any age - NCT00843375Recruiting
Testing stool samples to find early colon cancer and polyps
This study checks stool samples to see how well stool tests can detect early colon cancer and precancerous growths called adenomas. If you qualify, you’ll collect stool samples for a lab test (FIT) and sometimes this helps sort who should get follow-up testing.
Urbana, IllinoisAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Bloomington, IllinoisAges 60 years+ - NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Chicago, IllinoisAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Aurora, IllinoisAges 18 years+ - NCT06948084RecruitingPhase 2
New drug combo vs usual care for high-risk multiple myeloma
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
Bloomington, IllinoisAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Chicago, IllinoisAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Chicago, IllinoisAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Chicago, IllinoisAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Aurora, IllinoisAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Chicago, IllinoisAges 18–100 - NCT05363657Recruiting
Registry study for kidney tumor treatment choices
This study is a registry that collects information on how people with localized kidney tumors are treated (either active treatment or watchful waiting). It may help doctors better understand which approaches work best for different patients.
Chicago, IllinoisAges 18 years+ - NCT07779967Recruiting
Alcohol, breast cancer, and metabolism study
This study looks at how drinking alcohol while breastfeeding might affect a mother's body and possibly her risk for breast cancer. If you are nursing and drink alcohol, you may help researchers learn more about this connection.
Urbana, IllinoisAges 21–45 - NCT05629494RecruitingPhase 4
Ibuprofen vs PSA blood test for prostate evaluation
This trial studies whether an anti-inflammatory medicine (ibuprofen) changes prostate-specific antigen (PSA) blood test results to help decide on next diagnostic steps like MRI or biopsy. It may help people with an elevated PSA understand whether follow-up testing is more or less likely to be needed.
Chicago, IllinoisAges 18–80 - NCT07665372Recruiting
Liver transplant from donors with HIV for people with HIV
This study tests whether giving people with HIV a liver from an HIV-positive donor is safe and works well. It looks at infections, cancer risks, and long-term health after transplant.
Chicago, IllinoisAges 18 years+ - NCT06426628Recruiting
Nasal swab test for lung nodule risk
This trial tests a new nasal swab test to help doctors better understand your risk if you have a small lung nodule. The test looks at cells from your nose to give more information about whether the nodule might be cancer, without needing a biopsy right away.
Chicago, IllinoisAges 29–85 - NCT07647250Recruiting
Physical activity study for pancreatic cancer patients before surgery
This study tests if a personalized physical activity program can help pancreatic cancer patients who are receiving chemotherapy before surgery. It is designed for patients who feel weak or have early signs of frailty.
Chicago, IllinoisAges 18 years+
Cancer trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting cancer studies listed above.
- Northwestern University · 6 studies
- Cancer Care Specialists of Illinois - Decatur · 5 studies
- Decatur Memorial Hospital · 5 studies
- Northwestern Medicine Cancer Center Warrenville · 5 studies
- Southern Illinois University School of Medicine · 5 studies
- Illinois CancerCare-Bloomington · 4 studies
- Illinois CancerCare-Canton · 4 studies
- Illinois CancerCare-Carthage · 4 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Illinois?
- Yes. We're currently tracking 679 recruiting cancer studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.